S1128-118

Introduced

To establish special rules relating to information provided with respect to drug applications concerning method of use patents.

118th Congress Introduced Mar 30, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill provides special rules relating to method of use patents Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. It relies on definition changes, appropriations, compliance mandates, and product standards. The main policy areas are Healthcare Consumers and Healthcare.

Who Benefits and How

Patients and health care consumers affected by the bill could gain revenue opportunities and Public beneficiaries or protected communities affected by the clause could face reduced risk.

Who Bears the Burden and How

Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.

Key Provisions

  • Provides special rules relating to method of use patents Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill provides special rules relating to method of use patents Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Key Policy Areas

Healthcare Consumers, Healthcare

Primary Purpose

The bill provides special rules relating to method of use patents Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Policy Domains

Healthcare Consumers Healthcare

Whole bill

Identified Gains
  • Patients and health care consumers affected by the bill
  • Public beneficiaries or protected communities affected by the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: is
Patients and health care consumers affected by the bill:
Public beneficiaries or protected communities affected by the clause:
Identified Costs
  • Federal, state, or local agencies responsible for implementing the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: is
Federal, state, or local agencies responsible for implementing the clause:

Legislative Progress

Introduced
Introduced Committee Passed
Mar 30, 2023

Ms. Hassan (for herself and Mr. Braun) introduced the following …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Consumers Healthcare

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology